A Study of Sinotecean on Tolerance and Pharmacokinetics
This study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of Sinotecean.
Advanced Cancer
DRUG: Sinotecean
Pharmacokinetic Assessments for Area Under Curve（AUC）, To collect point with single drug:5 min/10 min/15 min/30 min/1 h/2h/4h/6 h/8h/10h/12 h/24 h/32h/48 h, Day 1-2 Single Dose|Pharmacokinetic Assessments for Cmax, Day 1-2 Single Dose|Pharmacokinetic Assessments for Tmax, Day 1-2 Single Dose
Objective Response Rate （ORR), each 42 days up to intolerance the toxicity or progression of disease（PD） (up to 24 months)|Maximum tolerated dose(MTD), up to 24 months|Dose-limiting toxicity(DLT), up to 24 months
This study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of Sinotecean.